Terms: = Ovarian cancer AND STIL, SIL, 6491, ENSG00000123473, Q15468
60 results:
1. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to BRCA1 status.
Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
[TBL] [Abstract] [Full Text] [Related]
2. Histopathologic and Preneoplastic Changes in Tubal Ligation Materials.
Ömeroğlu E; Ünlü Y; Uğur Kılınç AN; Günler T; Günenc O
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138220
[No Abstract] [Full Text] [Related]
3. Pathological findings and long-term prognosis in Korean BRCA1/2 mutation carriers undergoing risk-reducing salpingo-oophorectomy.
Kang OJ; Lee SW; Kim JH; Park JY; Suh DS; Kim DY; Kim JH; Kim YM; Kim YT
Int J Gynecol Cancer; 2023 Nov; 33(11):1743-1749. PubMed ID: 37541685
[TBL] [Abstract] [Full Text] [Related]
4. Prevalence of precursor lesions (P53 signature, SCOUT, stil, STIC) in fallopian tubes resected for non-neoplastic causes.
Tewari S; Misra V; Kumar V; Mishra RR; Yadav K; Paridhi ; Sangma H
Indian J Pathol Microbiol; 2022; 65(3):610-616. PubMed ID: 35900489
[TBL] [Abstract] [Full Text] [Related]
5. Inflammatory markers in women with reported benign gynecologic pathology: an analysis of the Prostate, Lung, Colorectal and ovarian cancer Screening Trial.
King LA; Wentzensen N; Purdue MP; Katki HA; Pinto LA; Trabert B
Ann Epidemiol; 2022 Apr; 68():1-8. PubMed ID: 34906633
[TBL] [Abstract] [Full Text] [Related]
6. Prognostic value of preoperative soluble interleukin 2 receptor α as a novel immune biomarker in epithelial ovarian cancer.
Li H; Wu M; Wu Z; Liang J; Wang L; Yang X; Lin Z; Li J
Cancer Immunol Immunother; 2022 Jun; 71(6):1519-1530. PubMed ID: 34724091
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
[TBL] [Abstract] [Full Text] [Related]
8. Prophylactic risk-reducing salpingo-oophorectomy in BRCA mutation carriers: what is going on in a region of northern Italy?
Grandi G; Perrone AM; Perrone A; Mandato VD; Comerci G; Sammarini M; Merisio C; Amadori A; Stefanetti M; Martinello R; Facchinetti F; De Iaco P;
Maturitas; 2021 Jan; 143():59-64. PubMed ID: 33308637
[TBL] [Abstract] [Full Text] [Related]
9. Cytoreductive surgery including distal pancreatectomy with splenectomy in advanced stage ovarian cancer: Two centers analysis.
Erturk A; Kuru O; Akgor U; Boyraz G; Cakir C; Turan T; Ozgul N; Salman C; Yuce K
Taiwan J Obstet Gynecol; 2020 Nov; 59(6):862-864. PubMed ID: 33218402
[TBL] [Abstract] [Full Text] [Related]
10. Multisite Tumor Sampling Reveals Extensive Heterogeneity of Tumor and Host Immune Response in ovarian cancer.
Lakis S; Kotoula V; Koliou GA; Efstratiou I; Chrisafi S; Papanikolaou A; Zebekakis P; Fountzilas G
Cancer Genomics Proteomics; 2020; 17(5):529-541. PubMed ID: 32859631
[TBL] [Abstract] [Full Text] [Related]
11. Fallopian tube abnormalities in uterine serous carcinoma.
Steenbeek MP; Bulten J; Snijders MPLM; Lombaers M; Hendriks J; van den Brand M; Kraayenbrink AA; Massuger LFAG; Sweegers S; de Hullu JA; Pijnenborg JMA; Küsters-Vandevelde HVN; Reijnen C
Gynecol Oncol; 2020 Aug; 158(2):339-346. PubMed ID: 32409160
[TBL] [Abstract] [Full Text] [Related]
12. The Association and Significance of p53 in Gynecologic cancers: The Potential of Targeted Therapy.
Nakamura M; Obata T; Daikoku T; Fujiwara H
Int J Mol Sci; 2019 Nov; 20(21):. PubMed ID: 31689961
[TBL] [Abstract] [Full Text] [Related]
13. Genomic landscape and evolutionary trajectories of ovarian cancer precursor lesions.
Wu RC; Wang P; Lin SF; Zhang M; Song Q; Chu T; Wang BG; Kurman RJ; Vang R; Kinzler K; Tomasetti C; Jiao Y; Shih IM; Wang TL
J Pathol; 2019 May; 248(1):41-50. PubMed ID: 30560554
[TBL] [Abstract] [Full Text] [Related]
14. The role of the interleukin (IL)-6/IL-6 receptor axis in cancer.
Taher MY; Davies DM; Maher J
Biochem Soc Trans; 2018 Dec; 46(6):1449-1462. PubMed ID: 30467123
[TBL] [Abstract] [Full Text] [Related]
15. Fallopian Tube Lesions in Women at High Risk for ovarian cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract] [Full Text] [Related]
16. The CHK1 inhibitor SRA737 synergizes with PARP1 inhibitors to kill carcinoma cells.
Booth L; Roberts J; Poklepovic A; Dent P
Cancer Biol Ther; 2018; 19(9):786-796. PubMed ID: 30024813
[TBL] [Abstract] [Full Text] [Related]
17. Retroperitoneal lymphadenectomy for ovarian cancer with double inferior vena cava.
Matsuoka A; Tate S; Nishikimi K; Shozu M
Gynecol Oncol; 2018 Mar; 148(3):632-633. PubMed ID: 29307453
[TBL] [Abstract] [Full Text] [Related]
18. Risk reduction surgery (RRS) for tubo-ovarian cancer in an Irish gynaecological practice: an analysis of indications and outcomes.
Thompson C; McCormick C; Kamran W; O'Riain C; Norris L; Gallagher D; Gleeson N
Ir J Med Sci; 2018 Aug; 187(3):789-794. PubMed ID: 29299762
[TBL] [Abstract] [Full Text] [Related]
19. Risk-reducing Salpingo-Oophorectomy in Women at Higher Risk of ovarian and Breast cancer: A Single Institution Prospective Series.
Ricciardi E; Tomao F; Aletti G; Bazzurini L; Bocciolone L; Boveri S; Landoni F; Lapresa MT; Maruccio M; Parma G; Peccatori F; Petrella MC; Zanagnolo V; Colombo N; Maggioni A
Anticancer Res; 2017 Sep; 37(9):5241-5248. PubMed ID: 28870960
[TBL] [Abstract] [Full Text] [Related]
20. [Morphologic features of fallopian tubal epithelium in pelvic high-grade serous carcinoma].
Zhao RJ; Wang YY; Li Z; Wu KY; Kong LF; Zheng WX
Zhonghua Bing Li Xue Za Zhi; 2017 Aug; 46(8):542-547. PubMed ID: 28810294
[No Abstract] [Full Text] [Related]
[Next]
